MedTrace Logo

Polish Transcatheter Aortic Valve-in-Valve Implantation (ViV-TAVI) Registry

NCT03361046 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2020-10-22

No results posted yet for this study

Summary

In the past years a substantial shift away from mechanical heart valves occurred and bioprosthetic heart valves claimed majority of market shares irrespective of patients' age.This indicates that population with failed surgical bioprostheses requiring ViV-TAVI will grow significantly and therefore, meticulous prospective data collection is necessary for future analyses in order to better understand potential limitations of this procedure.

Conditions

  • Ventricular Outflow Obstruction, Left
  • Aortic Valve Stenosis
  • Aortic Valve Insufficiency

Interventions

DEVICE

Transcatheter Aortic Valve-in-Valve Implantation (ViV-TAVI)

Patients with failed aortic valve bioprostheses qualified for TAVI due to coexisting illnesses

Sponsors & Collaborators

  • Medical University of Warsaw

    lead OTHER

Principal Investigators

  • Zenon Huczek, MD, PhD · Medical University of Warsaw

  • Wojciech Wojakowski, MD, PhD · Medical University of Silesia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2023-12-31
Completion
2024-05-30
FDA Device
Yes

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03361046 on ClinicalTrials.gov